Alpha Teknova, Inc.
NASDAQ•TKNO
CEO: Mr. Stephen Gunstream
セクター: Healthcare
業種: Drug Manufacturers - Specialty & Generic
上場日: 2021-06-25
Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.
連絡先情報
時価総額
$148.44M
PER (TTM)
-8.6
14.3
配当利回り
--
52週高値
$7.48
52週安値
$1.91
52週レンジ
順位48Top 64.4%
3.3
F-Score
改良版 Piotroski 分析
6年ファンダメンタル
弱い • 3.3 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2020-2025
財務ダッシュボード
Q4 2025 データ
売上高
$9.98M+0.00%
直近4四半期の推移
EPS
-$0.09+0.00%
直近4四半期の推移
フリーCF
-$710.00K+0.00%
直近4四半期の推移
2025 Annual 決算ハイライト
主なハイライト
Revenue Growth Achieved Revenue reached $40.520M, increasing 7.4% from $37.745M in 2024, driven by Lab Essentials segment growth.
Gross Margin Expansion Gross profit increased 85.9% to $13.441M; margin improved significantly to 33.2% from 19.2% reported.
Net Loss Reduction Net loss reduced by $9.486M to $(17.259)M, reflecting a 35.5% improvement in overall operating results.
Positive Investing Cash Flow Net cash provided by investing activities was $10.700M, resulting from $29.000M in short-term investment maturities.
リスク要因
Historical Losses Persist Past operating losses incurred; future profitability uncertain if revenue growth fails to offset increasing operating expenses.
Supply Chain Disruption Risk Supply chain disruption from natural disasters or catastrophic events could negatively affect production, delivery, and product demand.
Customer Relationship Reliance Reliance on customer relationships; termination of major orders could cause temporary or permanent revenue loss.
Uncertain Future Capital Needs Future capital needs are uncertain; financing may be required but securing favorable terms is not assured.
見通し
Deepen Customer Workflow Integration Strategy focuses on increasing integration of custom and GMP products into customer development workflows for sustained growth.
Selective Geographic Expansion Plan to expand geographic reach outside the U.S., targeting select European markets with local supply gaps.
Growth in Therapeutic Modalities Expect growth driven by continued R&D investment in cell/gene therapy, mRNA, and molecular diagnostics markets.
Infrastructure Investment Commit to operational excellence via infrastructure investment to increase capacity and reduce custom product turnaround times.
同業比較
売上高 (TTM)
$727.33M
$296.15M
$278.39M
粗利益率 (最新四半期)
99.0%
86.3%
85.5%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| CGC | $524.81M | -1.5 | -52.9% | 23.1% |
| IRWD | $516.89M | 21.4 | -8.2% | 150.6% |
| SOPH | $351.89M | -4.2 | -117.0% | 38.6% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
0.6%
緩やかな成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要
深度リサーチ
次回決算:2026年5月14日
EPS:-$0.08
|売上高:$10.19M
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書 | 直近12ヶ月 |
|---|
データなし